Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers and lacks oestrogen receptor (ER), progesterone receptor (PR) expression, and human epidermal growth factor receptor 2 (HER2) amplification. Here, ERBB2 is linked to triple-negative breast carcinoma.